Birdwatch Note
2023-04-23 21:53:53 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
There is no evidence behind the claim Remdesivir is killing people. A meta-analysis demonstrated that Remdesivir is a safe therapeutic option. Excess mortality was attributed to COVID-19 https://pubmed.ncbi.nlm.nih.gov/34323191/ https://healthfeedback.org/claimreview/claim-that-antiviral-drug-remdesivir-killing-people-is-baseless/ https://jamanetwork.com/journals/jama/fullarticle/2778234
Written by 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1650128724564619264
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1650256703592574980
- noteId - 1650256703592574980
- participantId -
- noteAuthorParticipantId - 7554BE30DC1ACBA237371B5EFA9AFEE56A40F40178D64EB403F2D35E5AB5AD31 Participant Details
- createdAtMillis - 1682286833080
- tweetId - 1650128724564619264
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- There is no evidence behind the claim Remdesivir is killing people. A meta-analysis demonstrated that Remdesivir is a safe therapeutic option. Excess mortality was attributed to COVID-19 https://pubmed.ncbi.nlm.nih.gov/34323191/ https://healthfeedback.org/claimreview/claim-that-antiviral-drug-remdesivir-killing-people-is-baseless/ https://jamanetwork.com/journals/jama/fullarticle/2778234
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2023-04-23 21:53:53 UTC (1682286833080) |
1969-12-31 23:59:59 UTC (-1) |
2023-05-06 02:42:24 UTC (1683340944665) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
rated at | rated by | |
2023-05-01 17:26:39 -0500 | Rating Details | |
2023-04-29 19:01:21 -0500 | Rating Details | |
2023-05-05 22:34:09 -0500 | Rating Details | |
2023-05-13 01:54:17 -0500 | Rating Details | |
2023-05-15 18:16:26 -0500 | Rating Details | |
2023-04-23 19:59:48 -0500 | Rating Details | |
2023-04-23 20:33:09 -0500 | Rating Details | |
2023-04-23 17:09:42 -0500 | Rating Details | |
2023-04-23 21:07:01 -0500 | Rating Details | |
2023-04-23 23:02:36 -0500 | Rating Details | |
2023-04-23 17:47:42 -0500 | Rating Details | |
2023-04-23 17:06:02 -0500 | Rating Details | |
2023-04-23 20:17:11 -0500 | Rating Details | |
2023-04-23 20:19:53 -0500 | Rating Details | |
2023-04-23 20:34:44 -0500 | Rating Details | |
2023-04-23 17:10:31 -0500 | Rating Details | |
2023-04-23 20:01:43 -0500 | Rating Details | |
2023-04-23 21:27:36 -0500 | Rating Details | |
2023-04-23 22:07:29 -0500 | Rating Details | |
2023-04-23 20:02:27 -0500 | Rating Details | |
2023-04-23 20:22:56 -0500 | Rating Details | |
2023-04-23 20:52:09 -0500 | Rating Details | |
2023-04-23 21:23:20 -0500 | Rating Details | |
2023-04-23 21:23:05 -0500 | Rating Details | |
2023-04-23 19:34:59 -0500 | Rating Details | |
2023-04-23 20:24:33 -0500 | Rating Details | |
2023-04-23 17:13:36 -0500 | Rating Details | |
2023-04-23 22:19:26 -0500 | Rating Details | |
2023-04-25 09:55:04 -0500 | Rating Details | |
2023-04-23 17:11:35 -0500 | Rating Details | |
2023-04-23 22:13:46 -0500 | Rating Details | |
2023-04-23 20:00:54 -0500 | Rating Details | |
2023-04-23 20:21:56 -0500 | Rating Details | |
2023-04-23 17:05:03 -0500 | Rating Details | |
2023-04-23 20:08:01 -0500 | Rating Details | |
2023-04-23 21:59:13 -0500 | Rating Details | |
2023-04-23 20:39:34 -0500 | Rating Details | |
2023-04-23 21:21:49 -0500 | Rating Details | |
2023-04-23 22:06:01 -0500 | Rating Details | |
2023-04-23 22:11:00 -0500 | Rating Details | |
2023-04-23 21:40:02 -0500 | Rating Details | |
2023-04-23 21:27:21 -0500 | Rating Details | |
2023-04-23 19:43:06 -0500 | Rating Details | |
2023-04-23 20:52:33 -0500 | Rating Details | |
2023-04-23 17:13:48 -0500 | Rating Details | |
2023-04-23 22:48:17 -0500 | Rating Details | |
2023-04-23 21:14:06 -0500 | Rating Details | |
2023-04-23 22:01:36 -0500 | Rating Details | |
2023-04-23 21:31:14 -0500 | Rating Details | |
2023-04-26 13:20:17 -0500 | Rating Details | |
2023-04-23 20:10:21 -0500 | Rating Details | |
2023-04-23 22:21:28 -0500 | Rating Details | |
2023-04-23 22:58:00 -0500 | Rating Details | |
2023-04-23 20:15:41 -0500 | Rating Details | |
2023-04-23 22:10:22 -0500 | Rating Details | |
2023-04-24 00:10:06 -0500 | Rating Details | |
2023-04-23 20:40:08 -0500 | Rating Details | |
2023-04-23 21:40:22 -0500 | Rating Details | |
2023-04-23 23:43:08 -0500 | Rating Details | |
2023-04-24 02:08:33 -0500 | Rating Details | |
2023-04-23 19:59:48 -0500 | Rating Details | |
2023-04-23 20:33:09 -0500 | Rating Details | |
2023-04-23 17:09:42 -0500 | Rating Details | |
2023-04-23 21:07:01 -0500 | Rating Details | |
2023-04-23 23:02:36 -0500 | Rating Details | |
2023-04-23 17:47:42 -0500 | Rating Details | |
2023-04-23 17:06:02 -0500 | Rating Details | |
2023-04-23 20:17:11 -0500 | Rating Details | |
2023-04-23 20:19:53 -0500 | Rating Details | |
2023-04-23 20:34:44 -0500 | Rating Details | |
2023-04-23 17:10:31 -0500 | Rating Details | |
2023-04-23 20:01:43 -0500 | Rating Details | |
2023-04-23 21:27:36 -0500 | Rating Details | |
2023-04-23 22:07:29 -0500 | Rating Details | |
2023-05-05 22:34:09 -0500 | Rating Details | |
2023-04-23 20:02:27 -0500 | Rating Details | |
2023-04-23 20:22:56 -0500 | Rating Details | |
2023-05-13 01:54:17 -0500 | Rating Details | |
2023-04-23 20:52:09 -0500 | Rating Details | |
2023-04-23 21:23:20 -0500 | Rating Details | |
2023-04-23 21:23:05 -0500 | Rating Details | |
2023-04-23 19:34:59 -0500 | Rating Details | |
2023-04-23 20:24:33 -0500 | Rating Details | |
2023-04-23 17:13:36 -0500 | Rating Details | |
2023-04-23 22:19:26 -0500 | Rating Details | |
2023-04-25 09:55:04 -0500 | Rating Details | |
2023-04-23 17:11:35 -0500 | Rating Details | |
2023-04-23 22:13:46 -0500 | Rating Details | |
2023-04-23 20:00:54 -0500 | Rating Details | |
2023-04-23 20:21:56 -0500 | Rating Details | |
2023-05-15 18:16:26 -0500 | Rating Details | |
2023-04-23 17:05:03 -0500 | Rating Details | |
2023-04-23 20:08:01 -0500 | Rating Details | |
2023-04-23 21:59:13 -0500 | Rating Details | |
2023-04-23 20:39:34 -0500 | Rating Details | |
2023-04-23 21:21:49 -0500 | Rating Details | |
2023-04-23 22:06:01 -0500 | Rating Details | |
2023-04-23 22:11:00 -0500 | Rating Details | |
2023-05-01 17:26:39 -0500 | Rating Details | |
2023-04-23 21:40:02 -0500 | Rating Details | |
2023-04-23 21:27:21 -0500 | Rating Details | |
2023-04-23 19:43:06 -0500 | Rating Details | |
2023-04-23 20:52:33 -0500 | Rating Details | |
2023-04-23 17:13:48 -0500 | Rating Details | |
2023-04-23 22:48:17 -0500 | Rating Details | |
2023-04-23 21:14:06 -0500 | Rating Details | |
2023-04-23 22:01:36 -0500 | Rating Details | |
2023-04-23 21:31:14 -0500 | Rating Details | |
2023-04-26 13:20:17 -0500 | Rating Details | |
2023-04-23 20:10:21 -0500 | Rating Details | |
2023-04-23 22:21:28 -0500 | Rating Details | |
2023-04-29 19:01:21 -0500 | Rating Details | |
2023-04-23 22:58:00 -0500 | Rating Details | |
2023-04-23 20:15:41 -0500 | Rating Details | |
2023-04-23 22:10:22 -0500 | Rating Details | |
2023-04-24 00:10:06 -0500 | Rating Details | |
2023-04-23 20:40:08 -0500 | Rating Details | |
2023-04-23 21:40:22 -0500 | Rating Details | |
2023-04-23 23:43:08 -0500 | Rating Details | |
2023-04-24 02:08:33 -0500 | Rating Details |